Biotech Values

[oc631]

Do you and the other doubters ever wonder why Teva has not simply told investors where Teva’s Lovenox knockoff comes from?

I'm not questioning the partnership with ItalFarmco. The approval of T-Lovenox not only would be a valuable asset for Teva but it's their chance to prove to the market they will be a leader in FOB. Besides Teva is too savvy to play the Lupenox game.